Advanced Gastric Adenocarcinoma
Conditions
Keywords
Paclitaxel, Olaparib, Pembrolizumab, Immunotherapy, Anti-PD-1, PARP inhibitors, Gastric Cancer
Brief summary
The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).
Interventions
DRUGPaclitaxel
Paclitaxel (80mg/m\^2) will be administered IV on days 1 and 8 starting with Cycle 2. Each Cycle is 21 days.
DRUGOlaparib
Olaparib (100mg or 300mg) will be administered orally on Days 1-21 of each Cycle. Each Cycle is 21 days.
DRUGPembrolizumab
Pembrolizumab (200mg) will be administered IV on day 1 of each Cycle. Each Cycle is 21 days.
Sponsors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Must have advanced gastric or gastroesophageal cancer. * Must have received only one prior line of systemic therapy for advanced disease and experienced disease progression on this regimen.. * For Cohort 1: Must have the presence of measurable lesion. * Must agree to have a biopsy. * Life expectancy of greater than 3 months. * Patients must have adequate organ and marrow function defined by study - specified laboratory tests. * Woman of childbearing potential must have a negative pregnancy test. * Must use acceptable form of birth control while on study. * Ability to understand and willingness to sign a written informed consent document.
Exclusion criteria
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Require any antineoplastic therapy. * Require any other form of systemic or localized antineoplastic therapy. * Has received prior therapy with paclitaxel or PARP inhibitor. Previous paclitaxel may be allowed if no progression on or within 6 months of receiving this drug. * Hypersensitivity reaction to any paclitaxel, pembrolizumab or related compounds and/or to any of the components. * Allergy to dexamethasone, diphenhydramine and famotidine. * Is taking a moderate or strong CYP3A inhibitor. * Has uncontrolled intercurrent acute or chronic medical illness. * Has a known additional malignancy that is progressing and has required active treatment within the past 1 year. * Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to study treatment. * Has received prior radiotherapy within 2 weeks of start of study treatment. * Has received a live vaccine within 30 days prior to the first dose of study drug. * Is currently or has participated in another investigational study within 4 weeks prior to receiving study drug. * Has an active known or suspected autoimmune disease. * Has a diagnosis of immunodeficiency. * Prior tissue or organ allograft or allogeneic bone marrow transplantation. * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. . * Requires daily supplemental oxygen. * History of (non-infectious) pneumonitis that required steroids or has current pneumonitis. * History of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent. * Infection with HIV or hepatitis B or C at screening. * Has uncontrolled infection requiring systemic therapy.. * Subjects unable to undergo venipuncture and/or tolerate venous access. * Has known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial. * Woman who are pregnant or breastfeeding. * A woman of childbearing potential (WOCBP) who has a positive urine pregnancy test within 72 hours prior to study drug initiation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 27 months | Overall survival is the time from the start of first dose of study drug to death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Events (AEs) | 15 months | When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject. Laboratory abnormalities that were asymptomatic and not clinically significant were excluded. |
| Number of Participants Experiencing Immune-related Adverse Events (irAEs) | 15 months | When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject. Laboratory abnormalities that were asymptomatic and not clinically significant were excluded. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORKatherine Bever, MD
Johns Hopkins Medical Institution
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 13 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 17 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 15 Participants |
| Region of Enrollment United States | 19 Participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 17 / 18 | 1 / 1 |
| other Total, other adverse events | 18 / 18 | 1 / 1 |
| serious Total, serious adverse events | 13 / 18 | 0 / 1 |
Outcome results
None listed